Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida.
Leerink's Global Healthcare Conference 2025
Presentation Date: Wednesday, March 12, 2025
Time: 1:00-1:40 p.m. ET
Webcast: Click here
Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor's website at http://capricor.com/news/events/.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown deramiocel to demonstrate immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. Deramiocel is currently in late-stage development for the treatment of Duchenne muscular dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'believes,' 'plans,' 'could,' 'anticipates,' 'expects,' 'estimates,' 'should,' 'target,' 'will,' 'would' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on November 14, 2024. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of deramiocel (CAP-1002) for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug and is not approved for any indications. None of Capricor's exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
Capricor Media Contact:Raquel ConaKCSA Strategic Communications rcona@kcsa.com212.896.1204
Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@capricor.com858.727.1755
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Nucor (NUE) Exceeds Market Returns: Some Facts to Consider
In the latest market close, Nucor (NUE) reached $124.68, with a +1.75% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 0.63%. Prior to today's trading, shares of the steel company had gained 2.01% over the past month. This has lagged the Basic Materials sector's gain of 4.58% and the S&P 500's gain of 6.29% in that time. The investment community will be closely monitoring the performance of Nucor in its forthcoming earnings report. In that report, analysts expect Nucor to post earnings of $2.21 per share. This would mark a year-over-year decline of 17.54%. Meanwhile, our latest consensus estimate is calling for revenue of $8.28 billion, up 2.55% from the prior-year quarter. For the full year, the Zacks Consensus Estimates project earnings of $7.88 per share and a revenue of $31.48 billion, demonstrating changes of -11.46% and +2.43%, respectively, from the preceding year. Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Nucor. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Nucor currently has a Zacks Rank of #3 (Hold). Investors should also note Nucor's current valuation metrics, including its Forward P/E ratio of 15.54. This valuation marks a premium compared to its industry's average Forward P/E of 10.69. Investors should also note that NUE has a PEG ratio of 0.78 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Steel - Producers industry was having an average PEG ratio of 0.94. The Steel - Producers industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 68, which puts it in the top 28% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nucor Corporation (NUE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither
A highly public feud between Tesla Inc (NASDAQ:TSLA) CEO Elon Musk and President Donald Trump took the world by storm last week and sent shares of the electric vehicle company lower. As the feud continues on, here's a look at where Benzinga readers stand. What Happened: A back-and-forth between Musk and Trump across social media platforms saw the two well-known individuals escalate a feud related to differences on the "Big Beautiful Bill." Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — The feud comes after Musk left his White House position working for the Department of Government Efficiency to spend more time working on his other companies, such as Tesla. Benzinga recently asked readers who they side with in the battle, which includes Musk criticizing the new debt the country will take on if the bill that Trump supports is passed by Congress. "In the feud between Donald Trump and Elon Musk, who are you more likely to publicly support?" Benzinga asked. Here are the results: Neither: 44% Elon Musk: 25% Donald Trump: 17% Both: 14% The poll found that a near majority said they would publicly support neither Trump or Musk in the feud between former friends. Of the two well-known candidates, Musk received the largest support with 25% of the poll, ranking ahead of Trump at 17%.Why It's Important: Over the weekend, the battle between Musk and Trump minimized some with the Tesla CEO deleting some of his tweets that brought some claims against the current president. Tweets about ending the SpaceX Dragon program were also deleted. A battle between Trump and Musk over the long run could see many losers, including the country's space program and the launch of robotaxis, with Musk a leader in both sectors and Trump able to slow down progress made by the billionaire. Tesla stock saw its largest one-day market capitalization drop last week on the heels of the feud. Tesla stock trades up 1.61% at $299.72 at publication on Monday versus a 52-week trading range of $167.42 to $488.54. The stock has fallen 15% over the last five days and is down 22% year-to-date in 2025. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 259 adults. Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
41 minutes ago
- Yahoo
McDonald's (MCD) Stock Sinks As Market Gains: What You Should Know
McDonald's (MCD) ended the recent trading session at $300.43, demonstrating a -1.43% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.25%, and the technology-centric Nasdaq increased by 0.63%. Coming into today, shares of the world's biggest hamburger chain had lost 2.29% in the past month. In that same time, the Retail-Wholesale sector gained 5.29%, while the S&P 500 gained 6.29%. Investors will be eagerly watching for the performance of McDonald's in its upcoming earnings disclosure. The company's upcoming EPS is projected at $3.13, signifying a 5.39% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $6.69 billion, indicating a 3.04% upward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $12.24 per share and a revenue of $26.35 billion, signifying shifts of +4.44% and +1.64%, respectively, from the last year. Investors should also take note of any recent adjustments to analyst estimates for McDonald's. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.25% rise in the Zacks Consensus EPS estimate. Currently, McDonald's is carrying a Zacks Rank of #3 (Hold). With respect to valuation, McDonald's is currently being traded at a Forward P/E ratio of 24.91. Its industry sports an average Forward P/E of 23.73, so one might conclude that McDonald's is trading at a premium comparatively. Meanwhile, MCD's PEG ratio is currently 3.18. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Retail - Restaurants was holding an average PEG ratio of 2.57 at yesterday's closing price. The Retail - Restaurants industry is part of the Retail-Wholesale sector. With its current Zacks Industry Rank of 185, this industry ranks in the bottom 25% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McDonald's Corporation (MCD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data
